SEC 10K Report
SEC 10K Report for Johnson & Johnson; NYSE: JNJ
ACCT 221
October 09, 2014
The purpose of this report is to provide analysis of SEC 10K for Johnson & Johnson (JNJ). JNJ was incorporated in the State of New Jersey in 1887. JNJ and its subsidiaries have approximately 117,900 employees worldwide engaged in the research and development, manufacture and sale of a broad range of 250 operating companies conduction business in all countries of the world. JNJ’s primary focus has been on products related to human health and well-being.
Most of Johnson and Johnson's success can be attributed to its emphasis on decentralized management, which allows for greater focus as the company blankets 250 countries across the world (Johnson and Johnson - Strategic Planning). For the last 120 years, Johnson and Johnson have been on the forefront of innovation for each of its three divisions, but it must continue to develop and grow in order to maintain its position for the future. This report will investigate, assess, and put forth recommendations to ensure continued success for Johnson and Johnson.
Income
Income statement presents information on the financial results of a company's business activities over a period of time. The income statement communicates how much revenue the company generated during a period and what cost it incurred in connection with generating that revenue. Net Sales for 2013 was $68,894 compared to 2012 at $68,974. Not much of sales production for 2013. Net earnings has been increasing since 2011, with earnings at $10,513 in 2012 to $13,831 in 2013. Cost of Goods Sold was $22, 342 and Gross Profit came in at $48,970. Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. Johnson & Johnson’s gross profit margin deteriorated from 2011 to 2012 but then improved from 67.7% in 2012 to 67.6% in 2013 not reaching in 2011 level of
ACCT 221
October 09, 2014
The purpose of this report is to provide analysis of SEC 10K for Johnson & Johnson (JNJ). JNJ was incorporated in the State of New Jersey in 1887. JNJ and its subsidiaries have approximately 117,900 employees worldwide engaged in the research and development, manufacture and sale of a broad range of 250 operating companies conduction business in all countries of the world. JNJ’s primary focus has been on products related to human health and well-being.
Most of Johnson and Johnson's success can be attributed to its emphasis on decentralized management, which allows for greater focus as the company blankets 250 countries across the world (Johnson and Johnson - Strategic Planning). For the last 120 years, Johnson and Johnson have been on the forefront of innovation for each of its three divisions, but it must continue to develop and grow in order to maintain its position for the future. This report will investigate, assess, and put forth recommendations to ensure continued success for Johnson and Johnson.
Income
Income statement presents information on the financial results of a company's business activities over a period of time. The income statement communicates how much revenue the company generated during a period and what cost it incurred in connection with generating that revenue. Net Sales for 2013 was $68,894 compared to 2012 at $68,974. Not much of sales production for 2013. Net earnings has been increasing since 2011, with earnings at $10,513 in 2012 to $13,831 in 2013. Cost of Goods Sold was $22, 342 and Gross Profit came in at $48,970. Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. Johnson & Johnson’s gross profit margin deteriorated from 2011 to 2012 but then improved from 67.7% in 2012 to 67.6% in 2013 not reaching in 2011 level of
References: Stock Analysis on Net. (2014). Statement of Cash Flows. Retrieved from http://www.stock-analysis-on.net/NYSE/Company/Johnson-Johnson/Financial-Statement/Statement-of-Cash-Flows Meola, A CONSOLIDATED BALANCE SHEETS At December 29, 2013 and December 30, 2012 Accounts receivable trade, less allowances for doubtful accounts $333 (2012, $466) 11,713